Evidence map›Paper›PMID 27941124›Full record

ArticleGenes & development2016

A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.

Kuntian Luo, Lei Li, Yunhui Li, Chenming Wu, Yujiao Yin, Yuping Chen, Min Deng, Somaira Nowsheen, Jian Yuan, Zhenkun Lou

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 101 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. UHRF1 Controls the Timing of RAD51 Removal During DNA Damage Repair Through Suppressing RFWD3.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Kuntian LuoResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Lei LiResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Yunhui LiResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Chenming WuResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Yujiao YinResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Yuping ChenResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Min DengDepartment of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Somaira NowsheenMedical Scientist Training Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic School of Medicine, Rochester, Minnesota 55905, USA.
Jian YuanResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Zhenkun LouDepartment of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Tongji University · CNWinnMed · USMayo Clinic · USShanghai East Hospital · CN

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Ubiquitination and the DNA Damage Response PathwayR01CA130996 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2008 to 2018
$3.3M
Regulation of homologous recombination and cancer cell response to chemoradiotherapyR01CA203561 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2016 to 2020
$1.8M
Deubiquitinases in regulation of BRCA1 pathwayR01CA203971 · NCI · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, LOU, ZHENKUN · 2016 to 2020
$1.8M
The Role of WSB1 in TumorigenesisR01CA189666 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2014 to 2018
$1.6M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA130996NCI NIH HHS R01 CA189666NCI NIH HHS R01 CA203561NCI NIH HHS R01 CA203971
6 · The paper itself

Abstract

Homologous recombination (HR) is one of the major DNA double-strand break (DSB) repair pathways in mammalian cells. Defects in HR trigger genomic instability and result in cancer predisposition. The defining step of HR is homologous strand exchange directed by the protein RAD51, which is recruited to DSBs by BRCA2. However, the regulation of the BRCA2-RAD51 axis remains unclear. Here we report that ubiquitination of RAD51 hinders RAD51-BRCA2 interaction, while deubiquitination of RAD51 facilitates RAD51-BRCA2 binding and RAD51 recruitment and thus is critical for proper HR. Mechanistically, in response to DNA damage, the deubiquitinase UCHL3 is phosphorylated and activated by ATM. UCHL3, in turn, deubiquitinates RAD51 and promotes the binding between RAD51 and BRCA2. Overexpression of UCHL3 renders breast cancer cells resistant to radiation and chemotherapy, while depletion of UCHL3 sensitizes cells to these treatments, suggesting a determinant role of UCHL3 in cancer therapy. Overall, we identify UCHL3 as a novel regulator of DNA repair and reveal a model in which a phosphorylation-deubiquitination cascade dynamically regulates the BRCA2-RAD51 pathway.

Indexed as

BRCA2 ProteinBreast NeoplasmsCell Line, TumorCysteine EndopeptidasesDNA RepairGene Expression Regulation, NeoplasticGene Knockout TechniquesHEK293 CellsHomologous RecombinationHumansMCF-7 CellsPhosphorylationPoly(ADP-ribose) Polymerase InhibitorsProtein BindingRad51 RecombinaseRadiation ToleranceBRCA2 ProteinBRCA2 protein, humanCysteine EndopeptidasesPoly(ADP-ribose) Polymerase InhibitorsRad51 RecombinaseUbiquitin ThiolesteraseUCHL3 protein, humanBRCA2deubiquitinationDNA damage responsehomologous recombinationRad51UCHL3

Identifiers

PMID27941124
PMCPMC5204351
OpenAlexW2560317077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.